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article under the CC BY-NC-ND licenseAbstract Treatment of large renal stones has changed considerably in recent years. The
increasing prevalence of nephrolithiasis has mandated that urologists perform more surgeries
for large renal calculi than before, and this has been met with improvements in percutaneous
stone surgery. In this review paper, we examine recent developments in percutaneous stone
surgery, including advances in diagnosis and preoperative planning, renal access, patient po-
sition, tract dilation, nephroscopes, lithotripsy, exit strategies, and post-operative antibiotic
prophylaxis.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nephrolithiasis presents a significant health concern for a
large number of individuals throughout the world.
Increasing rates of comorbidities known to correlate with
urinary stone disease, such as diabetes mellitus, hyper-
tension, and obesity, have all led to an increase in the
incidence of new stones in these individuals. For example,
as the prevalence of diabetes in the United States has
nearly doubled in the past 20 years, the number of pre-
sentations to the Emergency Department for stone episodes
rose from 178 per 100,000 patient visits to 340 per 100,000
patient visits roughly over the same time period [1,2]. This
increase in overall stone prevalence has been met with a
similar increase in large renal stones.du (C. Hartman).
y of Chinese Urological Associ
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(http://creativecommons.org/liRecent studies have shown that environmental factors
may also play a significant role in the development of
nephrolithiasis. For example, Chi et al. [3] demonstrated
significant differences in the stone composition of Chinese
patients living in North America compared to Chinese pa-
tients living in China. They found that patients in China
were more likely to have a lower body mass index (BMI),
present approximately 9 years earlier than Chinese Ameri-
cans, and form calcium oxalate stones. This suggests that
environmental factors may play a significant role in stone
formation, in addition to genetic factors.
Oberlin et al. [4] recently looked at patterns of treat-
ment for upper tract calculi. They found that during
2003e2012 the number of patients treated with uretero-
scopy rose from 40.9% to 59.6%, while the number ofation and SMMU.
n and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
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(ESWL) correspondingly decreased from 54% to 36.3%. The
rate of percutaneous nephrolithotomy (PCNL) stayed
roughly the same.
Our aim is to review the literature on PCNL and examine
new developments in percutaneous stone surgery in recent
years.
2. Diagnosis
A number of imaging modalities have been described to
diagnose nephrolithiasis, including ultrasound (US),
computerized tomography (CT), and plain X-rays. Non-
contrast CT has emerged as the imaging study of choice
because of relative cost-effectiveness, sensitivity for
diagnosing nephrolithiasis, and speed at which it can be
performed [5]. Low-dose CT is an acceptable option in
patients with a favorable body habitus. In cases in which
percutaneous surgery is anticipated for a large stone
burden, CT scans aid in classification of stone size, location
within the collecting system, and density. Additionally,
they help in planning the operative approach a surgeon may
take in accessing a stone. In regions in which CT is not
readily available, renal US is a reasonable alternative for
diagnosing renal calculi, though the sensitivity and speci-
ficity of US is not as high as that of CT [6].
Okhunov et al. [7] recently proposed their S.T.O.N.E.
nephrolithometry scoring system to standardize reporting
for percutaneous nephrolithometry. In 117 patients from a
single institution, they measured five variables relating to
stone complexity based on pre-operative CT scan, including
stone size (S), tract length (T), obstruction (O), number of
calyces involved (N), and essence or stone density (E). They
found that pre-operative stone score correlated to post-
operative stone-free rate, estimated blood loss, operative
time, and length of stay. In follow-up, the group recently
validated the S.T.O.N.E. scoring system in a multi-
institutional study comprising 706 patients. Their results
confirmed their prior findings that a greater S.T.O.N.E.
score correlated with lower stone-free rates, increased
bleeding and estimated blood loss, operative time, length
of hospital stay, fluoroscopy time, and overall complication
rate [8].
Labadie et al. [9] recently compared three stone scoring
systems, including the S.T.O.N.E. scoring system, Guy’s
stone score, and the CROES (Clinical Research Office of the
Endourological Society) nephrolithometric nomogram to
determine which was the most predictive of surgical out-
comes. They found that each was significantly associated
with stone-free status, however Guy’s stone score and the
S.T.O.N.E. scoring system were significantly associated with
estimated blood loss (EBL) and hospital length of stay
(LOS), whereas the CROES nomogram was not predictive of
EBL or LOS.
Mishra et al. [10] also recently used CT urography and
three-dimensional volume rendering to assess staghorn
stone volume and correlate stone morphometry with the
number of tracts and stages needed to clear patients of
their staghorn stones. They then defined stones as one of
three types, with type 1 stones having a volume of less than
5000 mm3 with less than 5% of the stone volume in anunfavorable calyx, while type 3 stones were those with a
total volume greater than 20,000 mm3 and greater than 10%
of the stone in an unfavorable calyx. Type 2 stones were
those that fell between these two extremes. Through their
model they predict that type 1 stones necessitate a single
tract and single stage for stone clearance, type 2 stones
necessitate single tract-single/multiple stages or multiple
tracts within a single stage, and type 3 stones require
multiple tracts and stages for clearance.
These results argue that one of the recently developed
stone scoring systems should be used in preoperative
planning and patient counseling, and that this scoring sys-
tem should be universally used as a way to standardize
PCNL-planning across institutions.
3. Preoperative planning
The number of patients requiring PCNL who are on long-
term anticoagulation or antiplatelet therapy with warfarin,
aspirin, clopidogrel, and heparin derivatives has increased
in recent years due to the use of more drug-eluting cardiac
stents, heart valve replacements, treatment of atrial
fibrillation, and cardioprotective measures [11,12]. Con-
troversy exists as to which patients may be safely taken off
of anticoagulation for a period of time, as well as how to
best manage patients who need to remain on anti-
coagulation perioperatively. In patients with a significant
stone burden and in whom cessation of anticoagulation
poses an unacceptable risk, performing staged ureteros-
copies may be preferable to PCNL. In patients with signifi-
cant cardiac risk factors, cessation of aspirin may have
adverse cardiac consequences during the perioperative
period due to the rebound period off of aspirin. Recent
studies have also shown that low-dose aspirin can safely be
continued in the perioperative period without a signifi-
cantly increased risk of bleeding [13,14].
In patients undergoing procedures with a high risk of
bleeding such as PCNL, it is recommended that they dis-
continue the use of warfarin 3e5 days prior to the intended
procedure. Kefer et al. [15] specifically recommends stop-
ping warfarin 5 days prior to PCNL and waiting to restart it
for 5 days following the procedure. Low molecular weight
heparin may be used for bridging in the perioperative
period. The authors demonstrated this regimen to be safe,
with an acceptable major bleeding risk of 7%. The same
group demonstrated that stopping clopidogrel 10 days prior
to undergoing PCNL and resuming it 5 days postoperatively
incurred an acceptable bleeding risk, as well.
Sepsis secondary to urinary tract infection can signifi-
cantly increase morbidity and mortality in patients who
have undergone PCNL. It is standard practice for patients to
have a urinalysis and urine culture (UCx) checked prior to
undergoing surgery to reduce the risk of sepsis. Gutierrez
et al. [16] examined 5354 patients who underwent PCNL
and who had preoperative UCx available, and found that
865 (16.2%) patients had a positive UCx. Of the patients
with a positive culture, 18.2% developed a post-operative
fever in comparison to 8.8% of patients with a negative
pre-operative UCx. The type of microorganism was also
found to play a role, with as low as 9.7% of patients whose
urine was colonized with Staphylococcus species developing
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urine was colonized with Enterobacter species. In patients
who have a contaminated UCx, however, treatment de-
cisions become somewhat more difficult. Leavitt et al. [17]
recently reported on the use of urinalysis (UA) and urine
dipstick analysis (UDA) to predict the risk of sepsis after
PCNL. They found that of 291 patients with a negative UA or
UDA, none developed sepsis after undergoing PCNL. They
concluded that a negative UA or UDA may be sufficient as a
screening test prior to undergoing PCNL. At this time,
however, we continue to recommend obtaining a UCx prior
to PCNL in order to prevent sepsis.
Larson et al. [18] recently compared the bacterial spe-
cies between stone cultures (SCx) and UCx in patients un-
dergoing PCNL. They found that SCx and UCx correlated in
79% of cases. SCx was positive in 12.5% of patients who had
a negative UCx, and they therefore recommended obtain-
ing a stone culture at the time of PCNL in order to more
effectively tailor antibiotic treatment of sepsis after sur-
gery in patients with a negative UCx.
Controversy exists as to the best duration of preopera-
tive antibiotic treatment in patients scheduled to undergo
PCNL. Although many patients will have a negative UCx
preoperatively, approximately one-third of stones harbor
bacteria, despite the presence of antibiotic treatment.
Previous studies have demonstrated that one week of pre-
operative antibiotic therapy may reduce the risk of serious
infectious complications in patients who are at high risk for
infection but have sterile UCx. Larson et al. [19] recently
examined the differences in infectious complications in
patients with sterile urine who underwent PCNL and
received between 2 and 7 days of preoperative antibiotic
prophylaxis and who were deemed to be at high risk for
infectious complications. They found that there were no
patients who developed an infectious complication in
either group, including fever >38.5 C, SIRS criteria, or
sepsis after PCNL. They concluded that either 2 or 7 days of
prophylactic antibiotics are effective at preventing infec-
tious complications in high-risk patients with sterile urine
who undergo PCNL.4. Access
Access to the collecting system for PCNL may be obtained
either in interventional radiology (IR) prior to definitive
stone management, or by the urologist at the time of PCNL.
Oftentimes, urologists who perform less percutaneous
stone surgeries will proceed with PCNL after access is ob-
tained by IR, while dedicated endourologists will gain ac-
cess by themselves. Ingimarsson et al. [20] compared
access obtained in IR to access obtained at the time of PCNL
by a urologist, examining differences in complications and
stone-free rates when access is obtained by each of these
groups. They found that endourologists were significantly
more likely to gain access in the 10th or 11th intercostal
spaces than interventional radiologists (47% vs. 14%,
p < 0.001). There was no difference in the rate of com-
plications between the two groups, including pneumo-
thorax requiring intervention, transfusion, or failed access.
They did, however, find that patients for whom access was
obtained by an interventional radiologist underwent moresecondary procedures to become stone-free (38% vs. 21%,
p < 0.01). They concluded that access may safely be ob-
tained by either group, however these results argue that
urologists who gain access at the time of PCNL may achieve
a stone-free state with fewer procedures. This is likely due
to goal-directed access by endourologists to achieve stone-
free states, rather than to simply access the collecting
system.
Total fluoroscopy time and radiation exposure have also
come into scrutiny recently, especially amongst endourol-
ogists performing PCNL. The traditional “bullseye” tech-
nique for obtaining renal access has been criticized for long
fluoroscopy times. Lightfoot et al. [21] examined a novel
technique, utilizing laser-guided renal access and
compared the fluoroscopy time to traditional bullseye ac-
cess in a benchtop kidney model. They found that fluoros-
copy time was significantly reduced among all groups
examined, including attendings/fellows, residents, and
medical students when using laser-guided access. The least
experienced users, medical students and residents, re-
ported that laser-guided access was significantly easier to
learn than conventional access. These results argue that
laser-guided access may significantly reduce fluoroscopy
time when gaining renal access for PCNL, however these
results need to be confirmed in in vivo experiments, as
kidney models do not move with respiration as do in vivo
kidneys.
In a similar attempt to reduce fluoroscopy time during
PCNL, Alsyouf et al. [22] examined ureteroscopic-assisted
access in a recent feasibility study. Instead of using fluo-
roscopy, the authors placed a ureteroscope in the desired
calyx under direct visualization and then used ultrasound to
guide the access needle into that calyx. They found that
fluoroscopy time was significantly decreased in the
ureteroscopy-ultrasound group (4.6 s vs. 790 s, p < 0.001),
while operative time, stone-free rates, mean hospital stay,
estimated blood loss, and complication rates were not
significantly different between the two groups. Future
studies with a greater number of patients need to be per-
formed to confirm these findings.
Kawahara et al. [23] recently performed another study
utilizing ureteroscopy to gain renal access. In their study,
they inserted a nephrostomy puncture wire through the
ureteroscope and gained retrograde access to the collect-
ing system. While they used fluoroscopy and did not report
on fluoroscopy times or a comparison of radiation exposure
to conventional renal access, they did report that retro-
grade renal access was successful in 77.3% of patients.
Controversy also exists as to the safety of upper pole
renal access as compared to lower and middle pole access.
Some urologists believe that upper pole access may lead to
increased pain and complications, including thorascopic
complications. Lightfoot et al. [24] examined complica-
tions, narcotic use, stone burden, operative time, and
estimated blood loss between patients undergoing upper
pole access compared to lower pole access. They found
that patients undergoing upper pole access had an overall
greater stone-free rate (94.4% vs. 85.5%, p Z 0.024)
compared to patients undergoing lower pole access,
although complication rate, estimated blood loss, narcotic
requirements and operative time were similar between the
two groups. These results argue that for patients in whom
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and may lead to greater stone-free rates.
5. Position
Percutaneous nephrolithotomy has traditionally been
accomplished in the prone position. This requires first
performing a cystoscopy and ureteral catheter placement
in the lithotomy position and later repositioning the patient
in the prone position, or performing cystoscopy and ure-
teral catheter placement in the prone position, a technique
that many urologists are not comfortable performing.
Alternatively, PCNL may be performed in the supine posi-
tion, performing ureteral stent placement in lithotomy and
proceeding with PCNL without significant repositioning. The
advantage of this technique is also to be able to work both
from above and below at the same time.
Controversy exists, however, as to which technique is
superior in terms of operative time, stone-free rates, and
complications. Astroza et al. [25] recently published on
these topics, looking at 1311 patients who either under-
went supine (232 patients) or prone (1079 patients) PCNL.
They found that the stone-free rate was greater (p < 0.001)
and surgical time was shorter (p < 0.001) in patients who
underwent prone PCNL. They found that there was no dif-
ference in the complication rates between the two groups.
Conversely, a number of studies have examined the dif-
ferences between the two methods of PCNL and found that
operative time is shorter in patients undergoing supine
PCNL [26e29]. Numerous studies have also found that the
complication rates are similar between modalities
[26,28,29], transfusion rates or estimated blood loss are
similar [27,28], and stone-free rates are similar [26e29].
As it is easier to gain access to all calyces ureter-
oscopically than with a flexible nephroscope in patients
with multiple small stones in different calyces, it may be
beneficial to grasp these stones with the flexible uretero-
scope and release them in the renal pelvis. This then allows
these stones to be retrieved with the nephroscope more
easily. This is most easily accomplished with patients in the
supine position. This is especially relevant for PCNL per-
formed in the supine position as the tract is much longer
than the prone PCNL tract and consequently the long tract
makes it difficult to maneuver the nephroscope from one
calyx to another. We believe that endourologists should be
comfortable with performing PCNL in both the supine and
prone positions.
6. Tract dilation
Traditional tract dilation using successive Amplatz or Alken
dilators has recently been replaced by some urologists with
the use of balloon dilators. By rapidly dilating with a single
balloon rather than successively using different dilators,
balloon dilation is thought to be faster than successive
fascial dilation. Additionally, some believe that balloon
dilation may result in less renal trauma and a reduced risk
of dislodging the safety wire [30]. Fuller et al. [31] recently
examined the influence of BMI on PCNL outcomes and found
that, in obese patients, tract dilation was more commonly
performed via balloon dilation (p < 0.0001).One of the major criticisms of balloon dilators is their
relatively low burst pressure at 17 ATM. Recently developed
balloons have improved upon this, allowing pressures up to
30 ATM before concern for bursting exists. Hendlin and
Monga [32] reported a 100% success rate after dilating 60
nephrostomy tube tracts with a Bard X-Force 30 ATM
balloon, as opposed to the reported 5%e10% failure rate
with standard 17 ATM balloons.
Another new development in tract dilation has been the
introduction of the pathway access sheath (PAS), a device
that allows for tract dilation and sheath placement at the
same time. In a small study of only 21 patients, Pathak and
Bellman [33] compared access time between traditional
standard balloon dilation and the PAS system. They found
significantly reduced access time in those tracts dilated
with the PAS system (3 min vs. 5.7 min). These results need
to be confirmed in larger, prospective trials, but are
promising in potentially reducing the operative and fluo-
roscopy times amongst patients undergoing PCNL.
7. Nephroscopes
The standard rigid nephroscope has many advantages and
disadvantages related to its size. This scope requires a
calyceal tract to be dilated to 30 French, either via serial
fascial dilation or by balloon dilation. The large diameter of
the scope allows for excellent visualization within the col-
lecting system by providing good flow of irrigation and a
large visual field. The scope allows standard PCNL in-
struments to pass through it, such as more powerful ultra-
sonic lithotripters and graspers that can be used to remove
large stones. The 30 French calyceal tract allows for
removal of larger stone fragments intact, ostensibly
allowing for quicker stone clearance. However, the large
tract required by the standard rigid nephroscope possibly
results in more renal trauma upon dilation of the tract,
creating a higher risk of intraoperative and postoperative
complications. Standard PCNL may have a higher risk of
intraoperative blood loss, a higher postoperative risk of
pseudoaneurysm or arteriovenous malformation, and the
larger tract may contribute to more postoperative pain and
higher requirements for narcotics postoperative. Should
multiple percutaneous tracts be necessary, standard PCNL
is likely to increase the requirement for intraoperative and
postoperative transfusions and increase the bleeding risk.
Flexible nephroscopy provides a convenient way to sur-
vey the renal collecting system with direct visualization
without creating another tract. Using a standard flexible
cystoscope, one can survey the renal pelvis and most of the
calyces for residual stones, and even perform laser litho-
tripsy and use stone baskets to extract small residual
stones. If a large residual stone burden is noted, another
percutaneous tract may be created, however it is best to
limit the number of tracts as much as possible to lower the
risk of bleeding. While flexible nephroscopy is not perfect
and its reliability is user dependent, in skilled hands the
combination of rigid and flexible nephroscopy can effec-
tively clear a large stone burden while limiting the number
of percutaneous tracts required.
“Mini”-perc is a term used to describe a method of
percutaneous stone extraction utilizing a smaller
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calyx and the tract is usually dilated to 12-14 French, large
enough to accommodate a ureteral access sheath. Ure-
teroscopic instruments are then utilized, including flexible
and rigid ureteroscopes. Pediatric cystoscopes may also be
helpful. Smaller rigid nephroscopes, such as 12 French
nephroscopes, are available and can be used through a 14-
16 French Amplatz sheath as well. Li et al. [34] described
the use of an endoscopic pulsed perfusion pump combined
with retrograde flushing via a previously placed ureteral
catheter for removal of small fragments. The pump, which
irrigates via the endoscope, generates a pressure up to
300 mmHg for 3 s with a 2 s respite. This pressure, com-
bined with retrograde flushing, distends the collecting
system. With properly timed removal of the endoscope, a
relative vacuum is created within the sheath, forcing small
fragments out via the sheath. Guohua et al. [35] investi-
gated whether such a device contributed to high intrarenal
pressures, promoting pyelovenous backflow. They found
that the device created intrarenal pressures that were
generally lower than the level required for backflow. When
the level was reached, the pressure lasted only for a few
seconds and was soon relieved.
Mini-perc was originally designed for children with large
stones requiring percutaneous stone extraction [36], but it
has been shown to be useful for adults as well [37].
Generally used for stones less than 2 cm, mini-perc reduces
the morbidity of standard PCNL. The smaller tract poten-
tially creates a lower bleeding risk, both intraoperatively
and postoperatively. The smaller tract may also decrease
postoperative pain level, narcotic requirements, and hos-
pital length of stay. However, given the smaller tract,
visualization of the collecting system is worse than stan-
dard PCNL and efficiency of lithotripsy is limited by in-
struments available that fit through such small working
channels, including lasers, baskets, small suction devices,
and small grasping forceps. The stone fragments that are
removed must be much smaller to pass through the calyceal
tract. Thus, this technique is best for use in children or for
stones less than 2 cm in size.
Standard PCNL combined with mini-perc can be an
effective method to maximize stone-free rates while
minimizing complications. In a recent study, Wang et al.
[38] compared standard PCNL combined with mini-perc
versus single access standard PCNL, showing greater
stone-free rate in the PCNL/mini-perc group with similar
operative time, complication rate, and lower re-operation
rate.
Micro-PCNL is a new technique designed to minimize the
diameter of the calyceal tract. Micro-PCNL utilizes a 4.85
French optic needle, dubbed the “all-seeing needle”,
originally designed to obtain quicker percutaneous calyceal
access prior to dilation. This technique takes advantage of
the optic capability of the needle and uses this direct ac-
cess for lithotripsy [39], reducing the risk associated with
tract dilation. Given that the tract is approximately 16
Gauge, this technique seems to be best suited for small to
moderate size stones. However, it limits much of the
morbidity associated with standard PCNL and may be useful
for stones difficult to access ureteroscopically. Addition-
ally, this technique may find a niche in treating lower pole
stones which have poor clearance rates with ESWL.8. Lithotripsy
There are many different types of intracorporeal litho-
tripsy modalities that can be used with PCNL. The most
common modalities are homium:YAG laser, pneumatic
lithotripter, ultrasonic lithotripter, and combination de-
vices. Individually, ultrasonic lithotripters have been
shown to be more efficient for stone clearance than
pneumatic lithotripters [40]. However, combination
ultrasonic-pneumatic devices are more efficient for stone
clearance than either device individually [41]. These de-
vices are also combined with suction capability allowing
for greater efficiency. Laser lithotripsy is less efficient
than the other modalities, however its main advantage is
the flexibility of the laser fiber. This allows for lithotripsy
to be performed during flexible nephroscopy and ante-
grade flexibly ureteroscopy. A novel laser with suction
capabilities is under investigation. Another novel device
under investigation, PercSac, is a polyethylene sack used
to entrap a stone, controlling all of the stone’s fragments
during lithotripsy [42]. This device has been shown to
improve efficiency in stone fragmentation and improve
stone free rates in in vitro models.
9. Exit strategies
Renal drainage upon termination of PCNL has evolved over
time with a trend toward leaving smaller nephrostomy
tubes, and even with some urologists leaving patients
tubeless. Generally there are three main categories: large
nephrostomy tube drainage, small nephrostomy tube
drainage, and “tubeless” renal drainage in which the pa-
tient is left with a ureteral stent or ureteral catheter
instead of a nephrostomy tube.
For the most part, the large nephrostomy tube of choice
is a 24 French malecot re-entry nephrostomy tube. This is
accommodated within the calyceal tract of a standard
PCNL, its large diameter providing some tamponade of
bleeding from the tract. The large diameter also provides
low-pressure direct drainage of the kidney. The malecot
sits comfortably within the renal pelvis, helping to keep the
tube in place. The ureteral portion of the tube allows for
quick through-and-through access in cases where staged
procedures or re-operation is necessary. Thus, this tube is
preferred when the need for re-operation or staging is
suspected, after complicated cases with a large blood loss,
when gross stone is visible, or when there is complicated
anatomy [43].
An effort has been made to use smaller nephrostomy
tubes when possible. Smaller nephrostomy tubes have been
associated with less postoperative pain and narcotic re-
quirements when compared to 24 French malecot re-entry
tubes [44]. Different sizes of tubes can be used, from 8.5
French to 14 French. After uncomplicated cases, small
nephrostomy tubes are a safe alternative for renal
drainage.
“Tubeless” PCNL has recently become more popular and
has proven to be safe and viable. There are two ways to
promote renal drainage after tubeless PCNL: with a double-
J stent and Foley catheter, or with a ureteral catheter and
Foley catheter. When using a double-J stent, the Foley
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approximately 5e10 days after surgery. When using a ure-
teral catheter, both the Foley catheter and ureteral cath-
eter are removed 23e48 h after surgery. Zilberman et al.
[45] reviewed the use of tubeless PCNL and found this
technique decreased the need for pain medication in the
postoperative period, shortened hospital stay, and reduced
time to return to normal activities with no increase in
complications. It is recommended that tubeless PCNL be
reserved for straightforward, uncomplicated cases.
Tract sealants have been used in tubeless PCNL as sur-
rogates for nephrostomy tubes in an effort to facilitate
hemostasis and to prevent urinary extravasation. Agents
such as fibrin glue and FloSeal have been applied to caly-
ceal tracts with these objectives in mind. However, the
advantage to this practice remains theoretical. Shah et al.
[46] performed a prospective randomized trial utilizing
fibrin sealant after PCNL, finding no difference in blood
transfusion requirement and a trend toward less post-
operative pain and less analgesic requirement, though this
did not reach statistical significance.
Cryotherapy has also been used to facilitate tubeless
PCNL. Okeke et al. [47] utilized a cryoprobe within the
renal parenchyma just outside the collecting system, using
a 10-min freeze-thaw cycle, then removing the probe and
closing the skin incision. They found cryotherapy shortened
hospital stay, decreased rates of delayed bleeding, and
decreased rates of urinary leak.
The exit strategy for mini-perc has a similar dilemma
regarding which method of renal drainage is appropriate.
Sabnis et al. [48] performed a randomized controlled trial
comparing tubeless mini-perc with ureteral catheter and
Foley catheter, tubeless mini-perc with a double-J stent
and Foley catheter, and 14 French nephrostomy tube with
ureteral catheter and Foley catheter after mini-perc. They
found lower pain levels and pain medication requirements
in patients who underwent tubeless procedures and were
left with ureteral and Foley catheters, with no change in
drop in hemoglobin, urine leakage, or perioperative
complications.
10. Postoperative antibiotics
There are no clear guidelines for postoperative prophy-
lactic antibiotic choice and duration. In patients with
positive urine or stone cultures, these cultures should guide
antibiotic choice. Patients with postoperative fevers and
sepsis should be treated according to their clinical condi-
tion. Regarding routine prophylaxis post-PCNL, the AUA
recommends an initial perioperative prophylactic dose of
antibiotics, with prophylaxis continuing for 24 h post-
operatively [49]. There is some consideration given to
prolonging prophylaxis in anticipation of manipulating an
indwelling urinary tract catheter (Foley or nephrostomy
tube), however, in general prophylaxis should continue for
only 24 h.Conflicts of interest
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